Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche

Merck has struck a $1.9 billion deal to buy Pandion. The takeover will give Merck control of a pipeline of immune modulators led by a rival to IL-2 drugs in development at Amgen, Eli Lilly and Roche.